These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 34738550

  • 1. Human Angiopoietin-like Protein 3/ANGPTL3 Antibodies: Adding to the Armamentarium in the Management of Dyslipidemia.
    Wiggins BS.
    J Cardiovasc Pharmacol; 2021 Nov 01; 78(5):e631-e640. PubMed ID: 34738550
    [Abstract] [Full Text] [Related]

  • 2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K, Sharma M, Ferdinand KC.
    Nutr Metab Cardiovasc Dis; 2016 Oct 01; 26(10):853-62. PubMed ID: 27352986
    [Abstract] [Full Text] [Related]

  • 3. ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases.
    Luo F, Das A, Khetarpal SA, Fang Z, Zelniker TA, Rosenson RS, Qamar A.
    Trends Cardiovasc Med; 2024 May 01; 34(4):215-222. PubMed ID: 36746257
    [Abstract] [Full Text] [Related]

  • 4. New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins.
    Kim K, Ginsberg HN, Choi SH.
    Diabetes Metab J; 2022 Jul 01; 46(4):517-532. PubMed ID: 35929170
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence.
    Cicero AF, Tartagni E, Ertek S.
    Expert Opin Biol Ther; 2014 Jun 01; 14(6):863-8. PubMed ID: 24661068
    [Abstract] [Full Text] [Related]

  • 6. Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects.
    Filippatos TD, Liontos A, Christopoulou EC, Elisaf MS.
    Curr Vasc Pharmacol; 2019 Jun 01; 17(4):332-340. PubMed ID: 29424317
    [Abstract] [Full Text] [Related]

  • 7. Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.
    Agabiti Rosei E, Salvetti M.
    High Blood Press Cardiovasc Prev; 2016 Sep 01; 23(3):217-30. PubMed ID: 27567901
    [Abstract] [Full Text] [Related]

  • 8. New Trends in Dyslipidemia Treatment.
    Jang AY, Lim S, Jo SH, Han SH, Koh KK.
    Circ J; 2021 May 25; 85(6):759-768. PubMed ID: 33177309
    [Abstract] [Full Text] [Related]

  • 9. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
    Blom DJ, Dent R, Castro RC, Toth PP.
    Vasc Health Risk Manag; 2016 May 25; 12():185-97. PubMed ID: 27274264
    [Abstract] [Full Text] [Related]

  • 10. Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.
    Miyares MA, Davis K.
    Vasc Health Risk Manag; 2012 May 25; 8():483-93. PubMed ID: 22977305
    [Abstract] [Full Text] [Related]

  • 11. Evinacumab-dgnb (Evkeeza-REGN1500), A Novel Lipid-Lowering Therapy for Homozygous Familial Hypercholesterolemia.
    White RT, Sankey KH, Nawarskas JJ.
    Cardiol Rev; 2012 May 25; 32(2):180-185. PubMed ID: 37071085
    [Abstract] [Full Text] [Related]

  • 12. Moving Targets: Recent Advances in Lipid-Lowering Therapies.
    Larsen LE, Stoekenbroek RM, Kastelein JJP, Holleboom AG.
    Arterioscler Thromb Vasc Biol; 2019 Mar 25; 39(3):349-359. PubMed ID: 30676072
    [Abstract] [Full Text] [Related]

  • 13. Use of Low-Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitor Initiation.
    Rymer JA, Mues KE, Monda KL, Bratton EW, Wirtz HS, Okerson T, Overman RA, Brookhart MA, Muntner P, Wang TY.
    J Am Heart Assoc; 2020 May 05; 9(9):e014347. PubMed ID: 32326795
    [Abstract] [Full Text] [Related]

  • 14. What Do US Physicians and Patients Think About Lipid-Lowering Therapy and Goals of Treatment? Results From the GOULD Registry.
    Arnold SV, Cannon CP, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Alam S, Mues KE, Bhatt DL, Kosiborod M, GOULD Investigators.
    J Am Heart Assoc; 2021 Aug 17; 10(16):e020893. PubMed ID: 34369165
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.
    Shrestha P, van de Sluis B, Dullaart RPF, van den Born J.
    Cell Signal; 2019 Mar 17; 55():53-64. PubMed ID: 30550765
    [Abstract] [Full Text] [Related]

  • 19. A new dawn for managing dyslipidemias: The era of rna-based therapies.
    Macchi C, Sirtori CR, Corsini A, Santos RD, Watts GF, Ruscica M.
    Pharmacol Res; 2019 Dec 17; 150():104413. PubMed ID: 31449975
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.